vcvibes

Westlake Biopartners, LLC

SEC exempt reporting adviser (venture capital exemption).

HQ
CA

Westlake BioPartners is a life science venture capital firm that says people are central to its approach. It supports entrepreneurs from early ideation and preclinical research through clinical and commercial impact. The firm lists team members including a Finance Manager, a Director of Administration, and a VP of Finance and Operations. It also notes a portfolio company, Acelyrin, which merged with Alumis in 2025.

01 · Says / Does

TagSaysDoes
StagesNot statedNot enough dated deals
SectorsBiotechNot enough dated deals
RegionsCANot enough dated deals

Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.

02 · Fund history

FundYearSizeStatus
Westlake BioPartners Fund III, L.P.

Westlake BioPartners is a people-first life science venture capital firm that backs entrepreneurs from ideation and preclinical research through clinical and commercial impact, aiming to bring life-changing medicines to patients with unmet needs. Inferred from the firm's website

approx. 2023$450M to $456.01M (Form D and SEC adviser filing)Open, writing first checks
Westlake BioPartners Fund II, L.P.approx. 2020$450M (Form D)Follow-ons only

03 · People across funds

04 · Recent deals

No dated deals found yet.

05 · Latest from the firm

No news from the firm's website yet.

06 · Sources

  1. https://westlakebio.com/contact/
  2. https://westlakebio.com/people/
  3. https://westlakebio.com/about/
  4. https://westlakebio.com/portfolio/

Fund dates and sizes are from SEC Form D filings.

Last verified: Oct 28, 2026